Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD71. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD71. Methods of using these compounds for modulation of CD71 expression and for treatment of diseases associated with expression of CD71 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cREL. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cREL. Methods of using these compounds for modulation of cREL expression and for treatment of diseases associated with expression of cREL are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-12. Methods of using these compounds for modulation of G-alpha-12 expression and for treatment of diseases associated with expression of G-alpha-12 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interleukin-15. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin-15. Methods of using these compounds for modulation of Interleukin-15 expression and for treatment of diseases associated with expression of Interleukin-15 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Sentrin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Sentrin. Methods of using these compounds for modulation of Sentrin expression and for treatment of diseases associated with expression of Sentrin are provided.

Abstract: Antisense oligonucleotides are provided which are capable of inhibiting HBV replication. These oligonucleotides are specifically hybridizable with HBV RNAs which encode a P gene product, S gene product or C gene product, or with the 5' cap region, U5 region, .epsilon. region or translation initiation site of HBV RNA. Methods of diagnosing HBV infection, methods of inhibiting HBV replication, methods of treating an HBV infection and methods of treating or preventing HBV-associated diseases using the oligonucleotides of the invention are also provided. Such diseases may include acute hepatitis, chronic hepatitis, fulminant hepatitis, or hepatocellular carcinoma.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-13. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-13. Methods of using these compounds for modulation of G-alpha-13 expression and for treatment of diseases associated with expression of G-alpha-13 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-beta. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-beta expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-beta are provided.

Abstract: Compositions and methods are provided for modulating the expression of integrin .alpha.4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin .alpha.4 are preferred. Methods of using these compounds for modulating integrin .alpha.4 expression and for treatment of diseases associated with expression of integrin .alpha.4 are also provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoG. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoG. Methods of using these compounds for modulation of RhoG expression and for treatment of diseases associated with expression of RhoG are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-alpha. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-alpha expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-alpha are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of FAN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FAN. Methods of using these compounds for modulation of FAN expression and for treatment of diseases associated with expression of FAN are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-2. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-2 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-1. Methods of using these compounds for modulation of Akt-1 expression and for treatment of diseases associated with expression of Akt-1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEK2. Methods of using these compounds for modulation of MEK2 expression and for treatment of diseases associated with expression of MEK2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-1. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-1 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-11. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-11. Methods of using these compounds for modulation of G-alpha-1l expression and for treatment of diseases associated with expression of G-alpha-11 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ELK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ELK-1. Methods of using these compounds for modulation of ELK-1 expression and for treatment of diseases associated with expression of ELK-1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RhoA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoA. Methods of using these compounds for modulation of RhoA expression and for treatment of diseases associated with expression of RhoA are provided.

Abstract: Compositions and methods are provided for the modulation of ras expression. Oligonucleotides are provided which are targeted to nucleic acids encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions associated with ras are also disclosed.